213 related articles for article (PubMed ID: 29151702)
1. Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review.
Li CM; Liu ZC; Bao YT; Sun XD; Wang LL
World J Gastroenterol; 2017 Nov; 23(41):7478-7488. PubMed ID: 29151702
[TBL] [Abstract][Full Text] [Related]
2. Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report.
Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Hui K; Hu C; Ren Y; Jiang X
Medicine (Baltimore); 2017 Nov; 96(47):e8725. PubMed ID: 29381963
[TBL] [Abstract][Full Text] [Related]
3. Icotinib plus gemcitabine for metastatic pancreatic cancer: a case report.
Zhao J; Shen H; Hu HG; Huang JJ
World J Gastroenterol; 2015 Mar; 21(11):3441-6. PubMed ID: 25805958
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of advanced pancreatic liposarcoma with apatinib: A case report and literature review.
Han T; Luan Y; Xu Y; Yang X; Li J; Liu R; Li Q; Zheng Z
Cancer Biol Ther; 2017 Sep; 18(9):635-639. PubMed ID: 28678611
[TBL] [Abstract][Full Text] [Related]
5. Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.
Scott LJ
Drugs; 2018 May; 78(7):747-758. PubMed ID: 29663291
[TBL] [Abstract][Full Text] [Related]
6. Apatinib for the treatment of gastric cancer.
Roviello G; Ravelli A; Fiaschi AI; Cappelletti MR; Gobbi A; Senti C; Zanotti L; Polom K; Reynolds AR; Fox SB; Generali D
Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):887-92. PubMed ID: 27376400
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
[TBL] [Abstract][Full Text] [Related]
8. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer.
Roviello G; Ravelli A; Polom K; Petrioli R; Marano L; Marrelli D; Roviello F; Generali D
Cancer Lett; 2016 Mar; 372(2):187-91. PubMed ID: 26797419
[TBL] [Abstract][Full Text] [Related]
9. Apatinib for the treatment of gastric cancer.
Geng R; Li J
Expert Opin Pharmacother; 2015 Jan; 16(1):117-22. PubMed ID: 25420417
[TBL] [Abstract][Full Text] [Related]
10. The use of apatinib in treating primary pleural synovial sarcoma: A case report.
Chen S; Zhang K; Wan X; Chen Y; Ma S; Deng Q
Medicine (Baltimore); 2019 Dec; 98(51):e18382. PubMed ID: 31861000
[TBL] [Abstract][Full Text] [Related]
11. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
[TBL] [Abstract][Full Text] [Related]
12. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of apatinib combined with iodine-125 in chemotherapy-refractory advanced lung cancer: A case report.
Zhang Y; Yin S; Jia Y; Qin L
Medicine (Baltimore); 2020 Aug; 99(33):e21600. PubMed ID: 32872014
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance.
Fathi Maroufi N; Rashidi MR; Vahedian V; Akbarzadeh M; Fattahi A; Nouri M
Life Sci; 2020 Jan; 241():117106. PubMed ID: 31786193
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy with apatinib in a patient with relapsed small cell lung cancer: A case report and literature review.
Zhao J; Zhang X; Gong C; Zhang J
Medicine (Baltimore); 2017 Dec; 96(50):e9259. PubMed ID: 29390367
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of low-dose Apatinib in the management of stage IV luminal-type breast cancer: a case report and literature review.
Lv X; Chen J; Yi T; Lu H; Liu J; Yu D
Anticancer Drugs; 2021 Sep; 32(8):773-778. PubMed ID: 34145174
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study.
Guo Y; Tang J; Huang XE; Cao J
Medicine (Baltimore); 2019 Feb; 98(6):e13908. PubMed ID: 30732125
[TBL] [Abstract][Full Text] [Related]
18. Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case report.
Dong M; Bi J; Liu X; Wang B; Wang J
Medicine (Baltimore); 2016 Aug; 95(31):e4368. PubMed ID: 27495042
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
[TBL] [Abstract][Full Text] [Related]
20. Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma.
Zhou N; Liu C; Hou H; Zhang C; Liu D; Wang G; Liu K; Zhu J; Lv H; Li T; Zhang X
Oncotarget; 2016 Nov; 7(44):72373-72379. PubMed ID: 27738308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
